BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20230101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250325
DTEND;VALUE=DATE:20250328
DTSTAMP:20260515T044403
CREATED:20241127T122738Z
LAST-MODIFIED:20241127T122738Z
UID:40140-1742860800-1743119999@www.pharmajournalist.com
SUMMARY:4th Novel Conjugate Summit
DESCRIPTION:The field of conjugatable drugs is advancing at a rapid pace\, with major collaborations like Nurix & Pfizer for antibody-degrader conjugates and Bicycle & Novartis for radiopharmaceuticals\, which paves the way towards a new generation of more targeted\, safer and efficacious novel conjugated drugs. \nThe 4th Novel Conjugates Summit is the only event offering comprehensive insights into the latest innovations in bioconjugates. From antibody-degrader conjugates to bispecific ADCs and peptide drug conjugates\, join us to delve into each of their value propositions and navigate crucial considerations like target selection\, PK/PD profiles\, and translation into the clinic. \nConnect with 100+ experts from big pharma\, cutting-edge biotechs and conjugation and manufacturing providers\, all sharing crucial insights on striking success with new formats and payloads. \nNow is the time to expand your conjugate design toolkit to pursue emerging cancer targets and stay ahead in the race to deliver safer\, more targeted therapies beyond traditional ADCs Join us to explore the most promising new targeting vectors and payloads that are set to revolutionize the landscape of conjugated drugs in 2025!
URL:https://www.pharmajournalist.com/event/4th-novel-conjugate-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T044403
CREATED:20250127T202012Z
LAST-MODIFIED:20250127T202012Z
UID:40377-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:5th Wet AMD Diabetic Eye Disease Drug Summit
DESCRIPTION:With Merck’s acquisition of EyeBio for $1.3 Billion\, Roche’s Vabysmo launch success and multiple other phase II and III trials in DME\, DR\, RVO\, and Wet AMD\, there is plenty to discuss in the retinal vascular drug space as drug developers seek to new alternatives to anti-VEGF\, explore biosimilars\, and target retinal fibrosis and more to find truly transformative drugs for patients. \n \nThe 2025 Wet AMD & Diabetic Eye Disease Summit is set to be an essential meeting for industry leaders\, research innovators\, and clinical experts dedicated to transforming the landscape of retinal vascular disease treatments. \nWhat’s New for the 2025 Wet AMD & Diabetic Eye Disease Drug Summit? \n\nNew Strategies for Retinal Vascular Drug Clinical Trials: Delve into advanced strategies for designing clinical trials in Wet AMD and diabetic eye disease\, focusing on patient-specific factors and adaptive trial models with insights from Bayer and Aviceda Therapeutics\nEmerging Biomarker Approaches Wet AMD\, DR. DME & RVO: Explore the critical role of biomarkers and clinical endpoints in developing therapies for neovascular retinal disorders\, featuring discussions from Opus Genetics and Ocugen\nInnovative Oral Anti-Inflammatory Treatments for Diabetic Eye Disease: Discover how InflammX Therapeutics is addressing the unmet need in DR and DME patients non-responsive to anti-VEGF therapy with their once-daily oral small molecule\nAdvancements in Retinal Drug Delivery: Discover the benefits of suprachoroidal TKI delivery for Wet AMD with Clearside Biomedical\, and hear from Sanofi about incorporating drug delivery devices to improve physician efficiency and patient compliance\nBreakthroughs in Wet AMD Gene Therapy: Learn about emerging gene therapies for Wet AMD\, focusing on innovative approaches and potential impact on patient care with HuidaGene Therapeutics Doheny Eye Centers\n\nJoin 50+ biopharma experts from clinical\, medical\, regulatory. value and access departments from Bayer\, Sanofi\, EyePoint\, Ocular Therapeutix\, Clearside Biomedical\, RevOpsis\, Opus Genetics\, and HuidaGene Therapeutics as they accelerate towards releasing longer-lasting\, non-invasive and more effective drugs for retinal disease patients. \nTo know more visit: https://ter.li/sew767
URL:https://www.pharmajournalist.com/event/5th-wet-amd-diabetic-eye-disease-drug-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250318
DTEND;VALUE=DATE:20250321
DTSTAMP:20260515T044403
CREATED:20241107T144640Z
LAST-MODIFIED:20241107T144640Z
UID:40031-1742256000-1742515199@www.pharmajournalist.com
SUMMARY:The 5th Operationalize: Expanded Access Programs Summit
DESCRIPTION:Expanded Access Programs (EAPs) are increasingly recognized as an ethical imperative in modern healthcare. More companies are opening EAPs to provide critical therapies to patients who would otherwise lack access. However\, challenges persist\, especially when navigating the complex regulatory landscape of global programs. From country-specific regulations to post-trial access\, managing global supply chains\, importation\, licensing\, and labeling standards remains a critical focus for ensuring patients worldwide receive the treatments they need. \nJoin over 120 thought leaders from Access\, Medical Affairs\, Clinical Operations\, and Clinical Supply for an unparalleled opportunity to network\, exchange insights\, and explore innovative strategies for overcoming the regulatory and operational hurdles that complicate global access to life-saving therapies. \nAt this year’s summit\, you’ll gain actionable insights on successfully planning and executing Post-Trial Access Programs\, navigating the regulatory landscapes of the US\, LATAM\, Europe\, and South & East Asia\, and developing compliant\, effective global access strategies. You’ll also explore best practices for creating exit plans and transition strategies that address hurdles in reimbursement\, off-request processes\, and country-specific regulations—plus so much more! \nTo know more visit: https://ter.li/org1vd
URL:https://www.pharmajournalist.com/event/the-5th-operationalize-expanded-access-programs-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250311
DTEND;VALUE=DATE:20250314
DTSTAMP:20260515T044403
CREATED:20250211T125459Z
LAST-MODIFIED:20250211T125459Z
UID:40474-1741651200-1741910399@www.pharmajournalist.com
SUMMARY:6th Supply Chain & Logistics for Cell & Gene Therapies Summit
DESCRIPTION:The 6th Supply Chain & Logistics for Cell & Gene Therapies Summit is the ultimate practical guide for designing scalable\, traceable\, and resilient global supply chains to support the growing number of complex cell and gene therapies. It is an industry wide challenge and vital part of development\, to ensure safe and timely delivery to patients. This relies on robust global supply chains. \nThe 2025 summit will provide a comprehensive deep dive into end-to-end global supply chains for cell and gene therapies\, covering autologous\, allogeneic\, in vivo\, and ex vivo programs. This is the industry’s premier platform to hear from more than 20 leading voices spanning clinical and commercial drug developers\, trusted service providers\, and clinical experts who will be sharing solution-driven case studies. These will focus on key areas such as defining robust processes\, securing reliable material supplies\, implementing digital solutions\, and ensuring seamless traceability of chain of identity and custody throughout the cold chain. \nOur 90+ attendees will gain invaluable and actionable insights on how to become commercial-ready\, expand globally\, and enhance cross-functional collaboration. The summit will unite professionals from Supply Chain\, Logistics\, Sourcing\, Quality\, and Operations sectors\, who will share best practices in supply planning\, manufacturing\, packaging\, labeling\, and delivery. Together\, they will brainstorm practical solutions for an integrated approach that strengthens value chains. \nFor those planning or executing a scaled\, integrated CGT supply chain\, this summit provides a unique opportunity to innovate and address the logistical and operational challenges currently facing the industry. As the industry’s premier networking and knowledge-based event dedicated to optimizing cell and gene therapy supply chains\, you don’t miss out on this opportunity to network\, learn\, and collaborate with experts in the field. \nTo learn more about who will be attending including those from Novartis\, Beam Therapeutics\, Astellas Gene Therapies\, and more – download the event guide now. \nTo know more visit: https://ter.li/yjybt6
URL:https://www.pharmajournalist.com/event/6th-supply-chain-logistics-for-cell-gene-therapies-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250311
DTEND;VALUE=DATE:20250314
DTSTAMP:20260515T044403
CREATED:20241111T113610Z
LAST-MODIFIED:20241114T113531Z
UID:40065-1741651200-1741910399@www.pharmajournalist.com
SUMMARY:4th Cell Therapy Potency Assay Summit
DESCRIPTION:In the current cell therapy landscape\, where funding is tight and clinical development a priority\, developing robust potency assays is critical to avoid costly delays. Introducing the 4th Cell Therapy Potency Assay Summit\, uniting AD\, QC and regulatory experts\, this summit works to design potency assays that not only conform to changing guidelines but also streamline patient access to the next generation of cell therapies. \nJoin leading organizations like Arsenal Biosciences\, BlueRock Therapeutics\, the NIST and Vertex Pharmaceuticals\, as they share development strategies and the latest technologies needed to streamline your assay development workflows. You won’t want to miss out! \nTo know more visit: https://ter.li/inqax5
URL:https://www.pharmajournalist.com/event/4th-cell-therapy-potency-assay-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250303
DTEND;VALUE=DATE:20250307
DTSTAMP:20260515T044403
CREATED:20241128T113542Z
LAST-MODIFIED:20241128T113542Z
UID:40201-1740960000-1741305599@www.pharmajournalist.com
SUMMARY:15th World ADC London Summit 2025
DESCRIPTION:Antibody-drug conjugates remain front and centre of the biopharma world. Following Enhertu’s historic agnostic approval in HER2-positive solid tumours and TIVDAK winning full approval\, the field has seen a surge in multi-billion-dollar acquisitions\, commercialisation deals\, and licensing agreements. These developments have enabled the ADC community to make strides in bringing these therapies to earlier-line treatments and expand their use to wider patient populations. \nReturning for its 15th anniversary year\, World ADC London is the leading European conference uniting over 1000 ADC enthusiasts to maximise the therapeutic index of ADCs. Whether you are brand new to the field or have over a decade of experience\, work in discovery or manufacturing\, hold a strategic position or work day-to-day in the lab\, this meeting offers something for you! \nTake a look at the full agenda here. \nEmbark on a knowledge-rich adventure as we explore the intricate nuances of ADC development. From the initial stages of target identification and antibody engineering to the complexities of clinical trials and CMC strategies to navigating commercialisation\, expect to leave this event with a comprehensive understanding of the entire ADC lifecycle. \nHere are some of the leading minds sharing translatable lessons to advance your pipeline including: \n\nAlireza Tafazzol\, Senior Scientist II\, Oncology Bioinformatics\, AbbVie.\nOsama Chahrour\, Principal Scientist\, Chemical Development\, AstraZeneca.\nYu-Shin Hsu\, Research Analyst\, Independent.\nJinwon Jung\, Senior Director\, Protein Engineering\, ABL Bio.\nHayley Jackman\, Director\, CMC Regulatory Affairs\, AstraZeneca.\nLolke de Haan\, Vice President\, Toxicology\, ADC Therapeutics.\nMax Lee\, Associate Director\, AstraZeneca.\nPaul WolstenholmeHogg\, Vice President\, Medicinal Chemistry\, ADC Therapeutics.\nTomohiro Fujii\, ADC Researcher\, Ajinomoto Bio-Pharma Services.\nYing Buechler\, Chief Technology Officer\, Ambrx\, a Johnson & Johnson Company.\nPaul Jaminet\, Chief Executive Officer\, Angiex.\nUchechukwu OkorjiObike\, Senior Scientist\, Bioassay Development\, AstraZeneca.\n\nSee the full speaker faculty and session details here. \nDon’t miss this chance to unlock unmissable R&D\, focused industry networking opportunities\, and emerging trends taking hold of the ADC field with sessions from 120+ world-leading speakers including Daiichi Sankyo\, AstraZeneca\, Pfizer\, AbbVie\, Merck\, GSK\, Johnson & Johnson\, ADC Therapeutics and more.
URL:https://www.pharmajournalist.com/event/15th-world-adc-london-summit-2025/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:adc@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250303
DTEND;VALUE=DATE:20250306
DTSTAMP:20260515T044403
CREATED:20241008T141820Z
LAST-MODIFIED:20241008T141820Z
UID:39880-1740960000-1741219199@www.pharmajournalist.com
SUMMARY:10th Annual Innate Killer Summit
DESCRIPTION:2025 is shaping up to be the ‘bounce back’ year for natural killer therapy. For the first time we are seeing efficacious in-patient data\, expansion into autoimmune disease\, and combination approaches all take off! So\, we are proud to announce the 10th Anniversary Innate Killer Summit returning to San Diego this March\, to showcase all the above and much more. \nCarefully compiled alongside industry experts from Artiva Biotherapeutics\, Immunity Bio\, INmune Bio and UCL (just to name a few!)\, our agenda will provide you with the latest clinical data in NK cells\, engagers\, cytokines and more\, to revolutionize and accelerate innate therapies once again. \nAnd that’s not all! Owing to the overwhelming excitement\, in 2025 we will introduce a *BRAND-NEW* Applications of NK Biology to Autoimmunity Focus Day\, alongside critical workshops exploring cryopreservation and donor selection\, to provide your company with the NK insights needed to pave your future in innate immunity treatment. \nSecure your place to join us in celebrating a decade of uniting longstanding pioneers and trailblazers in the NK space! \nTo know more visit: https://ter.li/fqxr57
URL:https://www.pharmajournalist.com/event/10th-annual-innate-killer-summit/
LOCATION:DoubleTree by Hilton – San Diego Mission Valley\, 7450 Hazard Center Drive\, San Diego\, CA\, 92108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T044403
CREATED:20241204T185205Z
LAST-MODIFIED:20241204T185205Z
UID:40215-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:TRP Target Selection & Drug Design Summit
DESCRIPTION:The radiopharmaceutical race is on and pharma leaders such as AstraZenca\, BMS \, Eli Lilly\, Novartis and Sanofi are not getting left behind. Bolstering discovery pipelines through acquisitions of preclinical Mariana Oncology\, Radionetics and Aktis Oncology\, the field is turning to cutting-edge\, novel targeting molecules and new targets to address more unmet medical need. With strong clinical efficacy from blockbuster drugs Pluvicto and Lutathera\, radiopharmaceutical leaders are looking for the next application of this highly efficacious and potent modality! \nThe inaugural Targeted Radiopharmaceuticals Target Selection & Drug Design Summit is your dedicated forum to advancing novel radiopharmaceutical drug discovery. Delve deep into target mining\, screening\, discovery and selection from ROR1\, uPAR\, B7-H3\, NECTIN-4\, CAIX and more. Understand advances in radiobiological\, radiodecay and radiation absorption mechanisms to inform optimal targeting strategies from small molecule\, peptide\, nanobodies\, antibody fragments as well as linker and chelator technologies for enhanced PK. Bringing it all together\, gain a commercial perspective to enhance your strategic decision-making in target selection and novel drug rationale within this highly dynamic field. \nIncorporating key insights from radiopharmaceuticals’ leading drug discovery minds from medicinal chemistry\, radiobiology\, biology\, discovery\, R&D\, pharmacology\, computational biology\, commercial strategy and many more\, this is the only global opportunity to gain practical insights into your approaches\, from target selection to drug design. \nUniting the discovery experts pioneering the field\, join the inaugural TRP Target Selection & Drug Design Summit to understand exactly what targets match the strong therapeutic index of TRPs and uncover optimal targeting strategies for stellar drug discovery! \nTo know more visit: https://ter.li/95a3xm
URL:https://www.pharmajournalist.com/event/trp-target-selection-drug-design-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T044403
CREATED:20241031T112011Z
LAST-MODIFIED:20241031T112011Z
UID:39992-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:4th mRNA Analytical Development & Quality Control Summit
DESCRIPTION:4th mRNA Analytical Development & Quality Control Summit | February 25-27\, 2025 \nExcitement for mRNA therapeutics continues\, as RNA technologies are awarded the Nobel Prize for the second year running. Yet\, despite optimized analytics\, critical quality control methodology and robust assay development leading to efficient approvals and commercialization\, knowledge gaps persist in phase-appropriate assays\, analyzing LNP payloads and novel cell-targeted delivery systems\, and controlling dsRNA. Not to mention the challenges posed by regulations! \nWith exclusive FDA insight\, the 4th mRNA Analytical Development & Quality Control Summit returns; uniting the Analytical\, Quality\, and Assay Development teams at one central forum for the first time to finally address shared challenges and cross-department priorities to ensure successful regulatory submissions. \n\nDates: February 25-27\, 2025\nLocation: Revere Hotel Boston Common\, Boston\, Massachusetts\nEvent Program: https://ter.li/h10rnn\n\nBringing together 100+ Scientists\, Directors and Heads of Analytical Development\, Quality Control\, Assay Development\, CMC and Regulatory Affairs\, join your peers to take part in critical conversations and ensure the identity\, safety and efficacy of your RNA medicines. \nDownload the agenda here: https://ter.li/h10rnn \nView your registration options\, early bird savings\, and group discounts: https://ter.li/ku4oky \n 
URL:https://www.pharmajournalist.com/event/4th-mrna-analytical-development-quality-control-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T044403
CREATED:20241029T113934Z
LAST-MODIFIED:20241029T113934Z
UID:39973-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:8th CAR-TCR Summit Europe
DESCRIPTION:Investors in the cell therapy industry are actively looking into solid tumours\, autoimmune indications and novel engineering as the best place to allocate their money and resources. This\, along with the recent investments in Enara Bio\, ArsenalBio\, Kyverna and Artiva signifies that the field is poised to regain momentum. \nIt’s not just investments that are gaining traction. Recent approvals are changing the game\, with Iovance and Adaptimmune making strides in treating solid tumours\, Kite securing first-line treatment approval\, and donor cell therapies\, demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope! \nThe 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate\, innovate\, and overcome the shared challenges of safety concerns\, high cost of goods\, effective tumour targeting\, and more. Let’s work together to drive success in clinical trials\, secure regulatory approvals\, and position cell therapy as the first-line treatment for oncological and non-oncological indications. \nView the agenda here: https://ter.li/6qjg6t \nSnapshot of the 50+ expert speaker faculty: \n\nBirk Vanderween\, Senior Vice President\, Global Manufacturing & Supply\, Legend Biotech \nCokey Nguyen\, President & Chief Executive Officer\, Atara Biotherapeutics \nDanielle Quarles\, Executive Director\, Clinical Operations\, Sana Biotechnology\nFranco Locatelli\, Professor\, Catholic University of Sacred Heart\, Bambion Gesu Children’s Hospital \nGwendolyn Binder\, President\, Science & Technology\, Cabaletta Bio \nMarlene Carrasco Alfonso\, Global Head Immunology Cell Therapy\, AstraZeneca \nNancy Boman\, Chief Regulatory Officer\, Adicet Bio \nRaha Jahromi\, Associate Director\, Kite\, A Gilead Company\n\nLearn more: https://ter.li/6qjg6t
URL:https://www.pharmajournalist.com/event/8th-car-tcr-summit-europe/
LOCATION:ExCeL London\, Royal Victoria Dock\, 1 Western Gateway\, London\, E16 1XL\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250225
DTEND;VALUE=DATE:20250228
DTSTAMP:20260515T044403
CREATED:20241024T112821Z
LAST-MODIFIED:20241024T112821Z
UID:39941-1740441600-1740700799@www.pharmajournalist.com
SUMMARY:8th Antigen-Specific Immune Tolerance Drug Development Summit
DESCRIPTION:Advancing Curative Therapies for Autoimmune Diseases  \nBuilding on the success of last year’s meeting\, the 8th Antigen-Specific Immune Tolerance Summit will bring together 120+ end-to-end experts in immune tolerance for autoimmune diseases. \nAgenda highlights include: \n\nStandardizing the definition and biomarkers of tolerance to inform clinical endpoints for specific disease studies and work towards measurable milestones of efficacy\nDelving into antigen selection for complex autoimmune diseases with multiple antigen drivers to expand the wheelhouse of diseases immune tolerizing strategies can target including celiac disease\, Type 1 diabetes\, multiple sclerosis\, rheumatoid arthritis\, IBD\, and more\nAdvancing durable and efficacious ASIT therapeutics through early-stage clinical trials and beyond\n\nJoin your colleagues and thought leaders in February to take actionable insights back to your team at the industry’s only\, dedicated\, antigen-specific immune tolerance meeting. Join Eli Lilly\, AbbVie\, Pfizer\, Diamyd\, Moderna\, Toleranzia\, GRO Bio and more. \nFind out more here: https://ter.li/ujeia4
URL:https://www.pharmajournalist.com/event/8th-antigen-specific-immune-tolerance-drug-development-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250219
DTEND;VALUE=DATE:20250222
DTSTAMP:20260515T044403
CREATED:20241122T121650Z
LAST-MODIFIED:20241122T121650Z
UID:40111-1739923200-1740182399@www.pharmajournalist.com
SUMMARY:3rd Viral Vector Process Development & Manufacturing Summit
DESCRIPTION:In recent industry news\, AAV gene therapies are gaining momentum\, with groundbreaking achievements like RegenxBio’s RGX-121 trial for Hunter syndrome\, demonstrating significant improvements in neurodevelopmental skills. The global AAV therapy market\, valued at $1.5 billion in 2023\, is projected to skyrocket to $22.3 billion by 2029. However\, scaling up production remains a significant challenge\, highlighting the urgency for innovative solutions in viral vector manufacturing.​ \nThe 3rd Viral Vector Process Development & Manufacturing Summit returns to Boston to tackle these challenges head-on. Featuring over 16 expert speakers\, including Yuanli Song\, Associate Director at Sanofi\, the event offers cutting-edge insights into process optimization for viral vector production. Yuanli Song emphasized the importance of this summit\, saying\, “This summit is a vital platform that brings together experts from diverse fields to address and solve pressing challenges in viral vector process development and manufacturing. The 2025 meeting will witness valuable discussions that will help drive innovation and advance solutions for optimizing viral vector production.” \nThe agenda includes two interactive workshops and over 20 hours of insightful content designed to address upstream and downstream challenges\, improve yield\, and enhance scalability. Additionally\, attendees will benefit from 6+ hours of dedicated networking breaks\, fostering collaborations crucial for advancing this field. \nKey topics covered include: \n\nEnhancing capsid ratios and vector optimization\nInnovations in purification techniques\nSeamless tech transfer for scalability\nTackling high-dose production complexities\n\nThis summit is the ultimate opportunity for professionals from companies like Sanofi\, Kite\, Ultragenyx\, and others to stay at the forefront of viral vector manufacturing innovations. With 800+ gene therapy candidates in trials and the FDA’s evolving frameworks\, this event is essential for driving the next wave of scalable\, high–quality therapies​. \nView our agenda to find out more!
URL:https://www.pharmajournalist.com/event/3rd-viral-vector-process-development-manufacturing-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250218
DTEND;VALUE=DATE:20250220
DTSTAMP:20260515T044403
CREATED:20241127T124753Z
LAST-MODIFIED:20241127T124753Z
UID:40158-1739836800-1740009599@www.pharmajournalist.com
SUMMARY:Neuroscience Innovation Pharma Partnering Summit
DESCRIPTION:Significant breakthroughs in CNS biology\, coupled with innovative neuroscience technologies and a more supportive regulatory landscape\, have fueled increased investment and pharmaceutical interest in the CNS. \nWith AbbVie\, BMS\, and Lundbeck making major acquisitions in the last 12 months alone\, this wave of deal-making is redemption for biotech who kept the lights on and are building with greater strength than before. \nJoin the Neuroscience Innovation Pharma Partnering Summit to: \n\nConnect with a targeted critical mass of decision-makers aligned with your strategic and scientific goals.\nBuild stronger relationships with key pharma and investor contacts to emphasize your company’s competitive edge\nPosition your company at the front of scientific innovation to show where you add value\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:https://www.pharmajournalist.com/event/neuroscience-innovation-pharma-partnering-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250211
DTEND;VALUE=DATE:20250213
DTSTAMP:20260515T044403
CREATED:20250116T115239Z
LAST-MODIFIED:20250117T133524Z
UID:40306-1739232000-1739404799@www.pharmajournalist.com
SUMMARY:3rd Kinase Targeted Drug Discovery Summit
DESCRIPTION:The kinase drug discovery field is at a pivotal moment\, with recent breakthroughs from industry leaders such as Biogen\, A-Alpha Bio\, and Proxygen paving the way for exciting new approaches in targeting kinases\, particularly in targeted protein degradation. \nWith ongoing challenges including selectivity and resistance in small molecule inhibitors\, these hurdles limit the therapeutic applications and call for in-depth discussions focused on innovative future strategies for kinase targeted drugs. \nJoin 60+ peers at the 3rd Kinase Targeted Drug Discovery Summit; the premier\, target-specific conference designed to provide you with ground-breaking insights to revolutionize your kinase biology. \n\nDiscover cutting-edge developments in small molecule therapeutics\, including PROTACs\, molecular glues\, and allosteric inhibitors\nEnhance drug selectivity & tackle resistance head-on\, and identify optimal combination partners\nLead the charge in creating first-class kinase-targeted drugs that can ultimately combat disease indications and transform patient outcomes!\n\nAttendance is complimentary for drug developers & researchers (subject to T&Cs) – we’d love to welcome you to Boston in February!
URL:https://www.pharmajournalist.com/event/3rd-kinase-targeted-drug-discovery-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250129
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044403
CREATED:20241031T113348Z
LAST-MODIFIED:20241031T113527Z
UID:40005-1738108800-1738281599@www.pharmajournalist.com
SUMMARY:9th Tumor Models San Francisco Summit 2025
DESCRIPTION:Waves of new models are being validated. A wider industry shift to precision oncology is requiring more specific genetic models. Availability and cost-effectiveness of sequencing and computational tools are enabling better and more accessible characterization of therapeutic pathways than ever before. The challenges and opportunities in preclinical and translational research are constantly evolving\, and it has never been more critical to benchmark and share cross-industry learnings and case studies to de-risk the move to the clinic. \nReuniting 180+ Preclinical\, Translational\, Discovery\, Pharmacology\, and Biology experts to share case studies in improving target selection\, facilitating biomarker discovery\, and achieving clinical translatability\, the 9th Tumor Models San Francisco Summit is the definitive industry forum uniting the West Coast ecosystem of pharma and biotech to collaboratively advance the frontier of oncology research to the clinic.Dates: December 10-12\, 2024. \n5 Must-Attend Case Studies in 2025:\n\n\nInterrogate the translational relevance of humanized mouse models and investigate data indicating translational relevance to optimize selection criteria with Amgen\nNavigate ADC activity in immunocompetent models across syngenic and humanized models to assess clinical relevance and optimize dosing with AstraZeneca\nEvaluate T cell engagers with additional functionality and selection rationale for humanized mouse models including PBMCs\, transgenic and tox models with Zymeworks\nOptimize decision making in outsourcing or developing internal capabilities for translational studies through cost-benefit models across multiple modalities with AstraZeneca\nExplore combination dosing strategies in bispecifics and CAR-T therapies and evaluate toxicity in mouse models to optimize targeted cytokine therapies with Regeneron
URL:https://www.pharmajournalist.com/event/9th-tumor-models-san-francisco-summit-2025/
LOCATION:Grand Hyatt San Francisco\, 345 Stockton St\, San Francisco\, CA\, 94108\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044403
CREATED:20241127T123357Z
LAST-MODIFIED:20241127T123357Z
UID:40145-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:3rd Ophthalmic Drug Delivery Summit
DESCRIPTION:Fresh from the reapproval of Roche/Genentech’s Susvimo\, positive readouts for sustained release implants\, and suprachoroidal delivery revolutionizing gene therapy delivery to the retina\, matching the right delivery route to the right drug has become an unavoidable topic for ophthalmology biopharma. \nThe 3rd Ophthalmic Drug Delivery Summit is the premier gathering for the industry to discuss and explore innovations and future directions for ophthalmic device and formulation development. Delve into the latest in-depth analysis of intravitreal\, subretinal\, suprachoroidal and topical delivery and explore advancements in ophthalmic pharmacology. \nWith an ever-growing market opportunity\, the industry is in an arms race to demonstrate the clinical benefits of longer lasting efficacy and less invasive drug delivery through alternative administration routes and novel ocular devices. Reuniting 60+ ophthalmic delivery innovators in sunny San Francisco\, the 3rd Ophthalmic Drug Delivery Summit is the only industry-focused meeting dedicated to translating more efficacious\, longer lasting\, and less invasive retinal delivery. Across 3 jam-packed days\, join clinical and preclinical ocular experts\, ophthalmic device engineers\, product development leaders and formulation specialists to delve a range of ocular drug-delivery systems striving to maintain drug concentrations\, reduce dosage frequency\, and overcome ocular barriers. \nThis meeting is your one-stop-shop to gather key updates on cutting-edge technologies\, ophthalmic pharmacology and to compare routes of administration capabilities to overcome anatomical barriers\, enhance bioavailability\, and improve patient outcomes such as: \n\nOptimizing sustained release formulations and release kinetics to fine-tune dosing for long-lasting retinal delivery with Genentech\, Ocular and Alcon\nEvaluating the durability and safety of delivering drugs to the retina via suprachoroidal delivery with Everads\, Genentech and Clearside\nUtilizing gene therapy transduction via sub retinal and para retinal delivery to the retina with REGENXBIO\, GelMEDIX and Ray Therapeutics\nTroubleshooting species differences and biocompatibility with ocular models to accelerate delivery translation with Genentech and Wake Forest University\nOvercoming clinical trial hurdles and achieving operational synergies to streamline development with Aviceda\, AbbVie and Regeneron\n\nDon’t miss this exclusive opportunity to meet world class ophthalmic delivery experts from the likes of Genentech\, AbbVie\, Bayer\, Clearside Biomedical\, Ocular Therapeutix\, REGENXBIO\, Regeneron\, Eyepoint Pharmaceuticals\, and more.
URL:https://www.pharmajournalist.com/event/3rd-ophthalmic-drug-delivery-summit/
LOCATION:The Clift Royal Sonesta San Francisco\, 495 Geary St\, San Francisco\, CA\, 94102\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044403
CREATED:20241031T112719Z
LAST-MODIFIED:20241031T112719Z
UID:39999-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:3rd Molecular Glue Drug Development Summit
DESCRIPTION:The 3rd Molecular Glue Drug Development Summit is returning to bring together leaders across biopharma covering the depth and breadth of the molecular glue field from rational discovery to improving toxicity\, PKPD\, and late-stage development. Don’t miss out on the unparallel learning and networking opportunities on offer at this summit and join 90+ pioneering Directors\, Vice Presidents\, and Heads of Medicinal Chemistry\, Structural Biology\, and Drug Discovery to kickstart your 2025 R&D and fast-track your glues to patients in need faster. \nTo know more visit: https://ter.li/rwb5uq
URL:https://www.pharmajournalist.com/event/3rd-molecular-glue-drug-development-summit/
LOCATION:The Royal Sonesta Boston\, 40 Edwin H Land Blvd\, Cambridge\, MA\, 02142\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044403
CREATED:20241008T142442Z
LAST-MODIFIED:20241008T144847Z
UID:39886-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:6th RNAi-Based Therapeutics Summit
DESCRIPTION:RNAi Therapeutics holds more promise than ever in treating many diseases beyond the liver\, with momentum in this field growing stronger than ever. Breakthrough companies such as Argonaute RNA and Kate Therapeutics have secured funding to propel their innovative RNAi candidates and delivery platforms\, as well as pharma giants partnering with innovative biotech companies to advance RNAi candidates into the clinic. \n \nThe 6th RNAi-Based Therapeutics Summit is returning to Boston to showcase the latest delivery technologies\, data from clinically successful extra-hepatic targeting\, cutting-edge AI tools to assist payload design\, and breakthrough chemical modifications that enhance stability\, allowing for precise therapeutic delivery. \nUniting 70+ leaders of the RNAi world\, this Summit will empower experts to pioneer their RNAi candidates into clinically successful therapies. Bringing together technical and strategic experts from Novo Nordisk\, Alynlam\, Switch Therapeutics\, Aro Biotherapeutics\, Novartis\, Comanche Biopharma\, and more\, this meeting is a unique gathering of RNAi’s sharpest minds\, dedicated to progressing the next wave of RNAi therapeutics to improve healthcare for patients in need. \nWant to learn more? Download our official brochure here: https://ter.li/00r79n
URL:https://www.pharmajournalist.com/event/6th-rnai-based-therapeutics-summit/
LOCATION:W Boston\, 100 Stuart Street\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250128
DTEND;VALUE=DATE:20250131
DTSTAMP:20260515T044403
CREATED:20241008T141023Z
LAST-MODIFIED:20241008T141023Z
UID:39875-1738022400-1738281599@www.pharmajournalist.com
SUMMARY:4th mRNA-Based Therapeutics Summit Europe
DESCRIPTION:The 4th mRNA-Based Therapeutics Summit Europe returns to Frankfurt\, Germany as the industry’s premier forum dedicated to showcasing the hottest disease targets\, never-before-seen pre-clinical and clinical data\, and demonstrating key routes to commercial success for mRNA therapy and vaccine R&D pipelines. \nWhether you’re entering the mRNA arena for the first time or a well-seasoned mRNA veteran\, with two dedicated tracks of content spanning discovery through commercialisation\, this forum will equip you with the know-how and connections to make rapid advances in your work with partnering and collaborative networking opportunities spread throughout. \nAssembling 200+ mRNA enthusiasts from across Europe\, Asia and the globe\, this is your one-stop-shop to gain unparalleled overview of cutting-edge R&D innovations\, whilst diving deep into end-to-end development strategy to revolutionise the next wave of mRNA medicines towards clinical reality. \nDownload the event guide for full details: https://ter.li/qd1z5z
URL:https://www.pharmajournalist.com/event/4th-mrna-based-therapeutics-summit-europe/
LOCATION:Sheraton Frankfurt Airport Hotel & Conference Center\, Hugo-Eckener-Ring 15/Terminal 1\, Frankfurt am Main\, 60549\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250127
DTEND;VALUE=DATE:20250130
DTSTAMP:20260515T044403
CREATED:20241114T140137Z
LAST-MODIFIED:20241114T140346Z
UID:40094-1737936000-1738195199@www.pharmajournalist.com
SUMMARY:The 3rd Medical Device Software Development Summit Europe
DESCRIPTION:Integrating Expertise from Software Development\, Quality Assurance\, Regulatory Affairs\, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines\, AI & ML Enabled Software\, Cybersecurity\, & Agile Methodologies: \nThe European market is capturing 30% of the global medical device field driven by rapid advances in innovative software\, AI\, and ML. But as medical device developers are met with tedious submission processes\, ever-changing software patches\, and red tape at every turn\, it has never been more important to break out of cross-functional silos and stay two steps ahead of compliance guidelines. \nDedicated to unravelling a matrix of multi-layered European and global regulations\, mitigating vulnerabilities in security\, and managing updates to legacy devices\, the 3rd Medical Device Software Development Summit Europe is uniting medical device giants and innovative start-ups to share case studies and best practices in advancing and maintaining compliance of innovative software. \nReturning to Munich in January\, this Summit will be shining the spotlight on: \n\nWorking strategies shown through examples of documentation for AI enabled medical device software\nImplementing automation tools to establish feedback loops throughout the software development process\nImplementing rigorous data validation and cleansing processes to ensure reliability of training datasets for AI models\nCreating synergy between business and engineering through a unified data strategy\n\nUniquely positioned to share strategic guidance in optimising efficiency in regulatory submissions\, streamlining development processes\, and embedding compliant AI and ML in medical devices\, join 70+ CTOs\, Heads of Software\, Product\, RA\, and QA to harmonise cross-functional objectives\, accelerate time to market\, and optimise updates to legacy devices. \nCurious to find out more? Download the Agenda here: https://ter.li/5y1i73
URL:https://www.pharmajournalist.com/event/the-3rd-medical-device-software-development-summit-europe/
LOCATION:H4 Hotel Munchen Messe\, Konrad-Zuse-Platz 14\, Munchen\, 81829\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241211
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044403
CREATED:20241108T100238Z
LAST-MODIFIED:20241108T100238Z
UID:40052-1733875200-1734047999@www.pharmajournalist.com
SUMMARY:3rd PAT & Real Time Quality Summit
DESCRIPTION:Join 100+ leading PAT scientists\, engineers\, process development\, CMC\, MSAT and quality experts at the 3rd Annual PAT & Real Time Quality Summit. Explore cutting-edge data-driven case studies\, engage in dynamic roundtables and deep dive into KOL-led panel debates. This summit is your gateway to staying ahead of the innovation curve\, exceeding stakeholder expectations for faster time to market\, and unlocking significant ROI through transformative PAT and real-time quality control. \nWith drug developers and manufacturers facing closer scrutiny on product quality than ever before\, it’s time to make the most of evolving process analytical technology (PAT) to design robust and cost-effective control strategies to understand more about your biopharmaceutical products. \nRecent blockbusters like GLP-1 peptides have sparked unprecedented investment into advanced manufacturing strategies\, such as Novo Nordisk’s recent $11B acquisition to expand manufacturing capacity. The maturity of PAT tools and the development of sophisticated software and chemometrics now provide the perfect opportunity to revolutionize traditional quality and analytical approaches\, achieving the digital manufacturing maturity necessary for the future. \nDon’t miss your chance to connect ground-breaking technologies with real-world manufacturing investment decisions. This is the only PAT conference designed exclusively for the pharmaceutical and biopharmaceutical community\, where insights turn into action. \nTo know more visit: https://ter.li/e3xja8
URL:https://www.pharmajournalist.com/event/3rd-pat-real-time-quality-summit/
LOCATION:Philadelphia Airport Marriott\, Terminal B\, One Arrivals Road Terminal B\, Arrivals Rd\, Philadelphia\, PA\, 19153\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044403
CREATED:20241114T161818Z
LAST-MODIFIED:20241114T161908Z
UID:40104-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:The 4th Applied Biocatalysis & Enzyme Engineering Summit
DESCRIPTION:Join industry leaders like Eli Lilly\, Merck\, Novo Nordisk and Pfizer at the 4th Applied Biocatalysis & Enzyme Engineering Summit (December 10-12\, 2024 – Philadelphia\, PA). This is your perfect moment to network with enzyme discovery\, engineering\, biocatalysis\, and process chemistry professionals from both industry and academia. \nCapitalize on Enzyme Evolution through HTP Screening\, Advanced Engineering & Deploy Maturing Biocatalysis Techniques in Small Molecules & Complex Modalities. \nNow with a sharper focus on enzyme engineering and expanded coverage of biocatalysis-derived oligonucleotides\, peptides and other large biologics. Plus\, dive into brand-new biopharma case studies designed to boost enzyme efficiency and therapeutic yields. \nWhy Attend? \n– Revolutionize Biologics Development: Discover cutting-edge oligonucleotide production case studies that are setting new standards in biologics \n– Streamline Enzyme Discovery: Learn how to prioritize and engineer enzymes from early-stage proof of concept to accelerate your pipeline \n– Fast-Track Decision Making: Master modern prediction methods and sophisticated high-throughput techniques to refine enzyme selection \n– Optimize Small Molecule Biocatalysis: Gain insights from pharma-led projects focused on enhancing activity\, yields and green chemistry \nWhat to Expect? \n– Exclusive interactive discussions exploring ML-informed enzyme design techniques \n– Poster session opportunity to showcase your current work and gain feedback from 60+ senior peers \n– 20+ industry speakers to inspire you and help you take advantage of biocatalysis in its prime \n– Pharma and academia-led workshops to perfect enzyme decision-making and late process optimization \nLet’s innovate and elevate drug development pipelines together through the power of green biocatalysis. \nTo know more visit: https://ter.li/t9gd14
URL:https://www.pharmajournalist.com/event/the-4th-applied-biocatalysis-enzyme-engineering-summit/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044403
CREATED:20240930T131805Z
LAST-MODIFIED:20240930T131943Z
UID:39832-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th ADC Target Selection Summit
DESCRIPTION:The 4th ADC Target Selection Summit returns to outline approaches to identify and validate novel targets that can be clinically and commercially successful and discuss rationale behind selecting a target to support with the development of future first-in-class ADCs. \nWith sessions led by Almac Discovery\, AstraZeneca\, Bolt Biotherapeutics\, and many other industry leaders\, leave this meeting equipped to perform a strategic evaluation of when and how to approach developing an ADC against a novel target. Enhance this knowledge with exclusive insight from brand-new biotechs\, Epifold and GO Therapeutics striving to leave their mark on the ADC field by sharing their innovative strategy which has reaped success in novel ADC targeting. \nDon’t miss this opportunity to join an audience of 80+ highly focused biologists\, discovery researchers\, computational biologists and bioinformaticians\, as well as senior C-level and Alliance Management experts. End your 2024 ADC conference calendar with the perfect balance of scientific and strategic level conversations and gain the know-how to invigorate your target selection strategy and propel more ADCs to first-in-class therapeutics. \nView all the industry strategies\, innovation sessions and networking opportunities in the FREE event guide here: https://ter.li/un31n9
URL:https://www.pharmajournalist.com/event/4th-adc-target-selection-summit/
LOCATION:DoubleTree by Hilton Hotel\, San Diego Downtown\, 1646 Front Street\, San Diego\, CA\, 92101\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044403
CREATED:20240904T120903Z
LAST-MODIFIED:20240904T120903Z
UID:39686-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:8th Complement-Based Drug Development Summit
DESCRIPTION:With the community hailing the latest FDA-approved therapeutic with Novartis’ inhibitor of the alternative complement for PNH\, which inhibitor will be the next to harness the complement system for the development of groundbreaking therapies? \nWith assets in nephrology\, ophthalmology\, neurodegeneration\, and inflammation all progressing through to the clinic\, the immunology landscape is preparing to be shaken up with companies making huge strides to achieve and improve the efficacy of complement-targeted therapies. \nJoin 100+ industry leaders\, scientists\, and clinicians at the premier\, end-to-end\, 8th Complement-Based Drug Development Summit to shape the future of complementtargeted therapies. Across 3 days of content\, you can expect discussions spanning: \n\nStrategic targeting and preclinical breakthroughs for the next-generation of complement inhibitors and comprehensive insights into the complexities of the complement pathways and selection of inhibition targets\nNavigating complement clinical trials and exploring indication expansion strategy for complement inhibitors beyond their initial disease indication\nExploring the potential for combination therapies to overcome compensatory mechanisms and ensure patient comfort\nMoving from targeting rare disease with complement inhibitors to larger patient populations\nNavigating efficacy and safety of complement inhibitors to bring safer and more tolerable therapies to patients faster\n\nKey benefits of attending: \n\nDelve into the pathophysiology of different complement pathways for the specific targeting of acute and chronic inflammatory diseases with Apterion Therapeutics\, Annexon Bio\,and Sanofi to determine the most effective pathway when developing complement inhibitors\nExplore the potential for combination therapies with existing complement therapies and other modalities with CSL Behring for a more precise approach to hit inflammation and autoimmune diseases harder beyond complete immunosuppressive approaches.\nDiscuss the move from targeting rare diseases with complement inhibitors to more common diseases with IgM Biosciences\, Grid Therapeutics\,and Astellas\, to target larger patient populations\nEvaluate the value proposition of targeting complement proteins with advanced therapeutics such as RNAi and gene therapies to determine the optimal mode of action and make complement inhibitors more targeted with Beacon Therapeutics and Arrowhead Pharmaceuticals\n8 Brand New Data readouts focusing on the translational and clinical stages of complement inhibitor development to help you stay up to date as this field makes strides towards regulatory approval
URL:https://www.pharmajournalist.com/event/8th-complement-based-drug-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044403
CREATED:20240828T110543Z
LAST-MODIFIED:20240828T110543Z
UID:39644-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:7th RNA-Targeted Drug Discovery & Development Summit
DESCRIPTION:With Remix Therapeutics joining forces with Roche and Daiichi Sankyo partnering with Depixus\, there have been many valuable collaborations entering the RNA-targeting field\, accelerating efficacious and selective small molecules targeting RNA directly\, RNA-binding proteins\, and RNA/protein complexes. \nHence\, as the go-to meeting for the RNA-targeting small molecule community\, the 7th Annual RNA-Targeted Drug Discovery & Development Summit returns to Boston this December. Increase your knowledge of RNA tertiary structures\, delve into innovative preclinical modeling strategies\, and identify optimal chemical features for advancing specific\, efficacious\, and safe small molecules. \nCurated in collaboration with large pharma\, innovative biotech\, and leading academics\, the 7th RNA-Targeted Drug Discovery & Development Summit returns with 3 jam-packed days and unrivaled networking opportunities with the key stakeholders to accelerate the discovery of disease-relevant RNA\, optimize small molecule design\, and uncover novel targets on proteins\, enzymes\, and RNA/protein complexes to increase the landscape of treatable diseases. \nUnite with 100+ RNA Science\, Medicinal Chemistry\, Structural Biology & Biophysics experts from the likes of AstraZeneca\, Sanofi\, Novartis\, PTC Therapeutics\, ReviR Therapeutics\, Rgenta Therapeutics\, Accent Therapeutics\, and more at the most comprehensive and definitive event for the community\, the 7th RNA-Targeted Drug Discovery & Development Summit\, to accomplish faster and smoother translation of RNA-targeted therapies towards the clinic. \nTo know more visit: www.rna-drugdiscovery.com
URL:https://www.pharmajournalist.com/event/7th-rna-targeted-drug-discovery-development-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044403
CREATED:20240828T105923Z
LAST-MODIFIED:20240828T105923Z
UID:39639-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:4th Rare & Genetic Kidney Disease Drug Development Summit
DESCRIPTION:With recent accelerated approval wins\, positive clinical trial readouts\, progression through clinical pipelines and exciting mergers and acquisitions\, it has certainly been an industry-defining year for the rare and genetic renal space. \nIn the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients\, the 4th Rare & Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry\, academic KOL\, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations. \nJoin Mironid\, AstraZeneca\, Novartis\, Maza Therapeutics\, Harvard Medical School\, and more as you dive into critical topics investigating IgAN\, FSGS\, PKD\, Alport Syndrome and more therapeutic areas to foster partnerships and accelerate game-changing therapies into the clinic and to rare renal diseases patients in need. \nView the full event program here: https://ter.li/ncjxqh
URL:https://www.pharmajournalist.com/event/4th-rare-genetic-kidney-disease-drug-development-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241210
DTEND;VALUE=DATE:20241213
DTSTAMP:20260515T044403
CREATED:20240719T112018Z
LAST-MODIFIED:20240722T133910Z
UID:39410-1733788800-1734047999@www.pharmajournalist.com
SUMMARY:2nd Covalent Drug Discovery & Development Summit
DESCRIPTION:Discover & Develop Selective\, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology\, Immunology & Beyond \nThe covalency renaissance continues as biopharma race to unlock hard-to-target proteins across oncology\, immunology and CNS. Yet\, key challenges remain in balancing reactivity and sensitivity\, de-risking the ligandability of alternative residues\, and tackling PKPD disconnects and efficiency bottlenecks\, \nBringing together 100+ covalency experts\, the 2nd Covalent Drug Discovery & Development Summit returns as the only dedicated forum to comprehensively cover discovery to translation and clinical development of covalent therapeutics. \n\nDates: December 10-12\, 2024\nLocation: Hilton Boston Logan Airport\, Boston\, Massachusetts\nEvent Program: https://ter.li/bz5jjg\n\nDive into extensive technical content spanning target selectivity\, hit screening\, lead optimization and covalent warhead design\, network with over 100 heads\, directors and VPs of Proteomics\, Medicinal Chemistry\, Chemical Biology\, Discovery Biology and Pharmacology\, and hear from the brightest minds of academia as they share their latest findings. \nDownload the program here: https://ter.li/bz5jjg \nRegister your place here (and take advantage of group discounts of up to 20% when registering your team of two or more!): https://ter.li/8257lj
URL:https://www.pharmajournalist.com/event/2nd-covalent-drug-discovery-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T044403
CREATED:20240919T065329Z
LAST-MODIFIED:20240920T112649Z
UID:39788-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:5th Genome Editing Therapeutics Summit
DESCRIPTION:Just 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal CRISPR discovery\, Casgevy marks the first approved gene-editing therapy\, a major milestone for the field. This breakthrough signals the beginning of a revolution in treating genetic diseases\, with a rapidly growing pipeline of precision genome-editing techniques emerging. \n \nThe 5th Genome Editing Therapeutics Summit (formerly the CRISPR 2.0 Sumit) is the leading industry event dedicated to advancing gene-editing technologies in therapy. Attendees can expect data-rich presentations\, expert panels\, and interactive sessions covering both established and emerging technologies. The summit will explore key topics such as novel nucleases\, base and prime editing\, multiplex editing\, and precision tools enabling small and large genome modifications. Additionally\, it will highlight epigenome editing\, recombinase and transposon-based technologies\, and innovative delivery vehicles. \nOver three days\, industry and academic leaders will present the latest research on cutting-edge therapies\, discussing the safety\, precision\, and regulatory compliance necessary for successful development. This summit is the only event prioritizing drug development first\, with a strong focus on creating robust safety profiles\, detecting off-target effects\, and facilitating investigational new drug (IND) filings. \nParticipants will gain actionable insights to improve the precision and safety of their technologies\, enhancing their ability to perform targeted edits and streamline the path to the clinic for lead programs. \nJoin us and be part of the gene-editing revolution shaping the future of therapeutic development!
URL:https://www.pharmajournalist.com/event/5th-genome-editing-therapeutics-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T044403
CREATED:20240809T123626Z
LAST-MODIFIED:20240813T083728Z
UID:39561-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:Personalized Vaccine Summit
DESCRIPTION:The Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer Vaccine Summit) returns to Boston bringing together the top industry players developing individualized approaches across several modalities including mRNA\, DNA\, peptides\, viral\, dendritic cell and more to share how they are conquering common challenges\, developing novel bioinformatic strategies\, and achieving clinical efficacy. \nThis is the only conference uniting biopharma companies working on different vaccine modalities to develop an immune-responsive personalized cancer vaccine for one goal – cure cancer! Join the likes of BioNTech\, CureVac\, Imvax\, NousCom\, with our expert speaker faculty of leaders and industry pioneers\, for 3 days of content and 15+ deep dive case studies. \nInterested? Find out more here. https://ter.li/lg5a1h
URL:https://www.pharmajournalist.com/event/personalized-vaccine-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241203
DTEND;VALUE=DATE:20241206
DTSTAMP:20260515T044403
CREATED:20240808T111110Z
LAST-MODIFIED:20240808T111110Z
UID:39549-1733184000-1733443199@www.pharmajournalist.com
SUMMARY:6th Cell Therapy Analytical Development Summit
DESCRIPTION:As the field of cell therapy evolves\, integrating the latest technologies and robust analytical methods has never been more crucial. Join us at the 6th Cell Therapy Analytical Development Summit to discover how to enhance your analytical strategies and accelerate product development through IND and clinical trials\, leading to more efficient regulatory approval. \nWhy Attend? \n\nExplore the latest advancements in immunophenotype\, cell-based\, and molecular assays.\nConnect with over 40 industry leaders and experts from companies like Bristol Myers Squibb\, Takeda\, and Kite Pharma to delve into assay matrices\, phase-appropriate development\, and specifications.\nParticipate in discussions on overcoming challenges in product characterization\, assay development\, and scale-up\, sharing innovative technologies and best practices to advance cell therapies.\n\nJoin us to elevate the development of safe and effective autologous and allogeneic cell therapies to new heights! \nDownload the NEW 2024 program
URL:https://www.pharmajournalist.com/event/6th-cell-therapy-analytical-development-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR